Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Subscribe To Our Newsletter & Stay Updated